S E Combs1, S Gutwein, Ch Thilmann, P Huber, J Debus, D Schulz-Ertner. 1. Department of Radiation Oncology, German Cancer Research Center (DKFZ), INF 280, and University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. Stephanie.Combs@med.uni-heidelberg.de
Abstract
PURPOSE: To assess the feasibility, efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent glioblastoma multiforme. PATIENTS AND METHODS: From January 1995 to July 2003, 53 patients with histologically proven glioblastoma multiforme were treated at recurrence with fractionated stereotactic radiation therapy. A median dose of 36 Gy using a median fractionation of 5 x 2 Gy/week was applied. RESULTS: Median overall survival was 21 months, and median overall survival from the time point of re-irradiation was 8 months. The median time interval between primary and secondary radiation therapy was 10 months. In this patient population, no variables predicting longer overall survival could be determined. However, neurosurgical resection at relapse was associated with increased survival after re-irradiation (p=0.04), but left progression-free survival unaltered. Treatment was well-tolerated and no severe toxicities developed. CONCLUSION: Stereotactically guided fractionated re-irradiation is a safe and effective treatment modality in selected cases of recurring glioblastoma multiforme. Since this is not a randomized study, further evaluation in larger patient collectives is warranted. Also, based on recent results of radiochemotherapy in the treatment of primary glioblastoma multiforme, concomitant chemotherapy at relapse might be considered in the future.
PURPOSE: To assess the feasibility, efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent glioblastoma multiforme. PATIENTS AND METHODS: From January 1995 to July 2003, 53 patients with histologically proven glioblastoma multiforme were treated at recurrence with fractionated stereotactic radiation therapy. A median dose of 36 Gy using a median fractionation of 5 x 2 Gy/week was applied. RESULTS: Median overall survival was 21 months, and median overall survival from the time point of re-irradiation was 8 months. The median time interval between primary and secondary radiation therapy was 10 months. In this patient population, no variables predicting longer overall survival could be determined. However, neurosurgical resection at relapse was associated with increased survival after re-irradiation (p=0.04), but left progression-free survival unaltered. Treatment was well-tolerated and no severe toxicities developed. CONCLUSION: Stereotactically guided fractionated re-irradiation is a safe and effective treatment modality in selected cases of recurring glioblastoma multiforme. Since this is not a randomized study, further evaluation in larger patient collectives is warranted. Also, based on recent results of radiochemotherapy in the treatment of primary glioblastoma multiforme, concomitant chemotherapy at relapse might be considered in the future.
Authors: M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen Journal: Ann Oncol Date: 2001-02 Impact factor: 32.976
Authors: Stephanie E Combs; Sybille Gutwein; Daniela Schulz-Ertner; Michael van Kampen; Christoph Thilmann; Lutz Edler; Michael M Wannenmacher; Jürgen Debus Journal: Strahlenther Onkol Date: 2005-06 Impact factor: 3.621
Authors: M Deutsch; S B Green; T A Strike; P C Burger; J T Robertson; R G Selker; W R Shapiro; J Mealey; J Ransohoff; P Paoletti Journal: Int J Radiat Oncol Biol Phys Date: 1989-06 Impact factor: 7.038
Authors: Johanna Quick; Florian Gessler; Stephan Dützmann; Elke Hattingen; Patrick N Harter; Lutz M Weise; Kea Franz; Volker Seifert; Christian Senft Journal: J Neurooncol Date: 2014-02-15 Impact factor: 4.130
Authors: G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi Journal: J Neurooncol Date: 2010-11-05 Impact factor: 4.130
Authors: Kyle C Cuneo; James J Vredenburgh; John H Sampson; David A Reardon; Annick Desjardins; Katherine B Peters; Henry S Friedman; Christopher G Willett; John P Kirkpatrick Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-12 Impact factor: 7.038
Authors: Joshua T McKenzie; Jess N Guarnaschelli; Achala S Vagal; Ronald E Warnick; John C Breneman Journal: J Neurooncol Date: 2013-04-16 Impact factor: 4.130
Authors: Thomas Hundsberger; Detlef Brügge; Paul M Putora; Patrik Weder; Johannes Weber; Ludwig Plasswilm Journal: J Neurooncol Date: 2013-01-12 Impact factor: 4.130